MoonLake Immunotherapeutics, a clinical-stage biopharmaceutical company, engages in developing therapies. It is developing Sonelokimab, a novel investigational Nanobody therapy for the treatment of inflammation. The company is involved in conducting Phase II trials for hidradenitis suppurativa, psoriatic arthritis, ankylosing spondylitis, or radiographic axial spondyloarthritis. MoonLake Immunotherapeutics was founded in 2021 and is headquartered in Zug, Switzerland.
IPO Year: 2020
Exchange: NASDAQ
Website: https://www.moonlaketx.com
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 5/19/2025 | $61.00 | Peer Perform → Outperform | Wolfe Research |
| 3/18/2025 | $67.00 | Outperform | RBC Capital Mkts |
| 1/17/2025 | $62.00 → $82.00 | Neutral → Buy | Goldman |
| 11/5/2024 | $92.00 → $73.00 | Outperform | Wedbush |
| 8/26/2024 | Outperform → Peer Perform | Wolfe Research | |
| 6/25/2024 | $104.00 | Outperform | Oppenheimer |
| 4/2/2024 | $62.00 | Neutral | Goldman |
| 2/15/2024 | $77.00 | Outperform | Wolfe Research |
| 12/8/2023 | $72.00 | Buy | Citigroup |
| 11/2/2023 | $74.00 | Buy | Stifel |
4 - MoonLake Immunotherapeutics (0001821586) (Issuer)
4 - MoonLake Immunotherapeutics (0001821586) (Issuer)
4 - MoonLake Immunotherapeutics (0001821586) (Issuer)
4 - MoonLake Immunotherapeutics (0001821586) (Issuer)
4 - MoonLake Immunotherapeutics (0001821586) (Issuer)
4 - MoonLake Immunotherapeutics (0001821586) (Issuer)
4 - MoonLake Immunotherapeutics (0001821586) (Issuer)
4 - MoonLake Immunotherapeutics (0001821586) (Issuer)
4 - MoonLake Immunotherapeutics (0001821586) (Issuer)
4 - MoonLake Immunotherapeutics (0001821586) (Issuer)
4 - MoonLake Immunotherapeutics (0001821586) (Issuer)
4 - MoonLake Immunotherapeutics (0001821586) (Issuer)
Wolfe Research upgraded MoonLake Immunotherapeutics from Peer Perform to Outperform and set a new price target of $61.00
RBC Capital Mkts initiated coverage of MoonLake Immunotherapeutics with a rating of Outperform and set a new price target of $67.00
Goldman upgraded MoonLake Immunotherapeutics from Neutral to Buy and set a new price target of $82.00 from $62.00 previously
Wedbush resumed coverage of MoonLake Immunotherapeutics with a rating of Outperform and set a new price target of $73.00 from $92.00 previously
Wolfe Research downgraded MoonLake Immunotherapeutics from Outperform to Peer Perform
Oppenheimer initiated coverage of MoonLake Immunotherapeutics with a rating of Outperform and set a new price target of $104.00
Goldman initiated coverage of MoonLake Immunotherapeutics with a rating of Neutral and set a new price target of $62.00
Wolfe Research initiated coverage of MoonLake Immunotherapeutics with a rating of Outperform and set a new price target of $77.00
Citigroup initiated coverage of MoonLake Immunotherapeutics with a rating of Buy and set a new price target of $72.00
Stifel initiated coverage of MoonLake Immunotherapeutics with a rating of Buy and set a new price target of $74.00